We are live on ! Find out more

Edesa Biotech

EDSA

Market cap $39.9M

4.14 USD

0.00

0%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

4.07

-0.07

1.69%

1 day

0%

5 days

-3.27%

1 month

-27.5%

3 months

-43.67%

6 months

-46.16%

Year to date

176%

1 year

80%

5 years

-95.04%

10 years

-99.51%

About: Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Employees: 17

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of $0.0001 per pre-funded warrant. Each common share and pre-funded warrant is being sold in combination with an accompanying common share warrant to purchase one common share. The common share warrants will have an exercise price of $7.50 per share, will be immediately exercisable from the date of issuance and will expire on the earlier of (x) the 18-month anniversary of the original issuance date and (y) 30 days following the Company's public announcement of Phase 2 vitiligo topline data for EB06. The combined public offering price of each common share and accompanying common share warrant is $5.50. The combined public offering price of each pre-funded warrant and accompanying common share warrant is $5.4999, which represents the combined public offering price for the common shares and accompanying common share warrants less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Edesa has granted the underwriters a 30-day option to purchase up to an additional 681,825 common shares and accompanying common share warrants to purchase up to 681,825 common shares at the public offering price, less underwriting discounts and commissions.

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

Edesa Biotech Announces Proposed Public Offering

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has commenced an underwritten public offering of its common shares (or pre-funded warrants to purchase common shares in lieu thereof) and accompanying common share warrants to purchase common shares. In addition, Edesa expects to grant the underwriters a 30-day option to purchase additional common shares and accompanying common share warrants in an amount up to 15% of the total number of common shares (or pre-funded warrants in lieu thereof) and accompanying common share warrants to be offered in the public offering under the same terms and conditions. All common shares, pre-funded warrants and accompanying common share warrants are being offered by Edesa. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering.

Edesa Biotech Announces Proposed Public Offering

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2026 and provided an update on its business.

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $3.5 million to the Company, before deducting offering expenses payable by Edesa. The common shares were placed without an agent, underwriter, broker or dealer. Investors in the PIPE include Edesa's Chief Executive Officer and healthcare-focused investors. The PIPE is expected to close on or about June 15, 2026, subject to the satisfaction of customary closing conditions.

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress.

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it will present data on paridiprubart, its first-in-class anti-TLR4 antibody, at the 63rd European Renal Association (ERA) Congress, to be held June 3 – 6, 2026, in Glasgow, Scotland. The ERA Congress is one of the world's leading nephrology meetings, convening clinicians and researchers focused on kidney disease.

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2026 and provided an update on its business.

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today provided an update on preparations and reaffirmed enrollment timeline guidance for its Phase 2 clinical study of EB06 in moderate-to-severe nonsegmental vitiligo. The announcement coincides with the company's sponsorship and participation today at the Global Vitiligo Foundation (GVF) Annual Scientific Symposium in Denver, Colorado.

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today positive additional data from a Phase 3 study of paridiprubart.

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

See News Rankings

Price charts implemented using Lightweight Charts™